Roche's Enicepatide Meets Both Primary Endpoints In Phase II Trial, Delivering Dose-Dependent Glucose And Weight Reductions In Type 2 Diabetes And Obesity Patients
At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic controlIn patients with poor baseline glycemic control (HbA1c
Roche tested a new medicine for diabetes and weight loss. The medicine worked well at high doses, which is what the company hoped to see.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.